Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some high-level statements are generally consistent with the provided label (e.g., active ingredient zonisamide; key adverse-reaction terms like somnolence/dizziness; need to shake suspension; discard after opening; contraindication/sulfonamide hypersensitivity). However, the majority of claims concern generic substitution, therapeutic interchangeability, OTC/pharmacy availability, and switching practices—none of which are supported by the provided ZONISADE label excerpts. Several statements also include details about formulation/release characteristics and practical pharmacy substitution that are not present in the supplied labeling.
Category Scores
Accurate Statements
Zonisamide products vary by formulation and brand/generic version.
Label excerpt provided confirms ZONISADE is an oral suspension with a specified strength/dosage form (Section 3). The label provided does not explicitly discuss brand vs generic formulation differences.
The safest approach is to use the exact product prescribed, including the same strength and release characteristics.
Not explicitly supported in provided excerpts; however, the label includes specific dosage form/strength and administration instructions for ZONISADE oral suspension (Sections 2.3 and 3).
To identify generic zonisamide, the label should list the active ingredient as zonisamide.
Supported only in principle by label identification that zonisamide is the active ingredient of ZONISADE (Sections 1 and 12). The provided excerpts do not discuss generic labeling/labeler/manufacturer conventions.
Differences after switching between brand and generic are sometimes related to the specific formulation (inactive ingredients) or changes from dose timing or pill appearance, rather than the active drug itself.
Not supported in provided excerpts; label excerpt provided discusses metabolic acidosis, monitoring, and specific ZONISADE administration for suspension.
If seizure control changes after a switch, prescribers often review the dose and dosing schedule.
Not supported by provided excerpts; label describes recommended dosage changes and gradual taper on discontinuation (Sections 2.2 and 2.4) but does not describe switching practice.
If seizure control changes after a switch, prescribers often review whether the same strength and formulation were dispensed.
Not supported by provided excerpts; label provides specific dosage form/strength for ZONISADE but does not address pharmacy substitution or switching.
If seizure control changes after a switch, prescribers often review side effects such as sleepiness, dizziness, appetite changes, or GI upset.
Partially supported: label lists somnolence and dizziness and anorexia as common adverse reactions (Section 6.1). GI upset is not listed in the provided adverse-reaction excerpt.
Zonisamide is sold in the U.S. as generic and under brand names, including Zonegran.
Not supported or addressed by the provided ZONISADE excerpts.
Generic zonisamide has the same active ingredient (zonisamide) as the brand product.
The provided label confirms zonisamide is the active ingredient in ZONISADE (Sections 1, 3, and 12), but does not provide information about generic products.
Generic zonisamide is intended to have the same clinical effect as the brand product.
Not supported by the provided label excerpts.
Unsupported Statements
Generic zonisamide has the same active ingredient (zonisamide) as the brand product.
The supplied excerpts verify zonisamide is the active ingredient of ZONISADE, but they do not state anything about generic products or cross-product sameness.
Generic zonisamide is intended to have the same clinical effect as the brand product.
No label excerpt addresses generic therapeutic equivalence or interchangeability.
To identify generic zonisamide, the label should list the active ingredient as zonisamide.
The excerpt supports that ZONISADE contains zonisamide, but does not provide guidance for identifying generic products.
To identify generic zonisamide, the label includes a manufacturer/labeler name, which varies by generic product.
Not addressed by provided label excerpts.
To identify generic zonisamide, the label includes strength information (e.g., common oral strengths may exist depending on the product).
Section 3 provides ZONISADE strength, but the excerpt does not discuss generic strength availability across products.
Pharmacies can sometimes substitute a generic for the brand unless the prescription specifies 'dispense as written.'
Not addressed by prescribing information excerpts provided (Sections 1-14).
In general, generic zonisamide is considered therapeutically interchangeable with Zonegran because it uses the same active ingredient (zonisamide).
No provided label excerpt discusses interchangeability or comparison with Zonegran.
Therapeutic interchangeability of generic zonisamide with Zonegran can depend on the specific product, dose, and how the prescription is written.
Not addressed by provided label excerpts.
Differences after switching between brand and generic are sometimes related to the specific formulation (inactive ingredients) or changes from dose timing or pill appearance, rather than the active drug itself.
Not discussed in provided label excerpts.
If seizure control changes after a switch, prescribers often review the dose and dosing schedule.
The label provides recommended dosage titration for ZONISADE, but does not mention switching/substitution practice.
If seizure control changes after a switch, prescribers often review whether the same strength and formulation were dispensed.
Not discussed in provided excerpts.
If seizure control changes after a switch, prescribers often review side effects such as sleepiness, dizziness, appetite changes, or GI upset.
Somnolence/dizziness/anorexia are supported (Section 6.1), but GI upset is not supported by the provided adverse reaction excerpt and the 'after a switch' practice is not described.
Zonisamide products may have different formulation types described as release characteristics (e.g., immediate vs extended release).
Provided label excerpts only describe an oral suspension and do not discuss immediate/extended release or release characteristics.
Generic zonisamide is commonly available through retail and mail-order pharmacies.
Not addressed by prescribing information excerpts.
Availability of generic zonisamide can vary by dose and manufacturer.
Not addressed by prescribing information excerpts.
Contradictions
Important Omissions
No discussion (in the AI claims list) of label-required safety monitoring for metabolic acidosis (baseline and periodic serum bicarbonate) or other specific warnings (hyperammonemia/encephalopathy ammonia measurement; kidney stones; gradual taper to avoid withdrawal seizure risk).
Importance:
Moderate
No dosage form administration specifics for ZONISADE oral suspension (e.g., shake well before every administration; accurate measuring device; discard unused portion after 30 days after first opening) were included in the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While none of the AI statements directly contradict the provided label excerpts, many statements are unsupported by the label and focus on substitution/interchangeability and practical pharmacy behavior, which are not covered in the provided ZONISADE prescribing information. Additionally, key label monitoring and administration instructions are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are about generic substitution, interchangeability with Zonegran, and availability—none are supported by the provided ZONISADE label excerpts.
Suggested Improvement
Limit statements to label-supported facts from Sections 1, 2 (including administration/tapering/assessments), 3, 4, 5 (metabolic acidosis, hyperammonemia/encephalopathy, kidney stones, cognitive/neuropsychiatric reactions), 6 (common adverse reactions), and 7 (CNS depressants and other carbonic anhydrase inhibitors). If discussing substitution/interchangeability, cite the exact FDA labeling language or remove those claims.